Want to see ENOV full AI Analyst Report?
ENOV Stock Chart & Stats
$26.32
$0.83(1.85%)
At close: 4:00 PM EST
$26.32
$0.83(1.85%)
Day’s Range― - ―
52-Week Range$19.14 - $36.82
Previous CloseN/A
Volume391.51K
Average Volume (3M)1.20M
Market Cap
$1.19B
Enterprise Value$2.58B
Total Cash (Recent Filing)$33.13M
Total Debt (Recent Filing)$1.41B
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Jul 30, 2026EPS Estimate
0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.02
Shares Outstanding57,562,603
10 Day Avg. Volume1,113,047
30 Day Avg. Volume1,200,059
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.02
Price to Sales (P/S)0.67
P/FCF Ratio75.96
Enterprise Value/Market Cap2.16
Enterprise Value/Revenue1.13
Enterprise Value/Gross Profit1.99
Enterprise Value/Ebitda-3.44
Forecast
1Y Price Target
$42.33Price Target Upside60.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)3.65
Revenue Forecast (FY)$2.35B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Solid Gross MarginEnovis has sustained revenue expansion with an underlying gross margin near 60%, providing a durable profitability buffer. A high gross margin base supports reinvestment in R&D and commercial expansion, giving the company pricing flexibility and resilience against cost pressures over the medium term.
Recon Segment Leadership And InnovationRecon's above-market growth, instrument/system rollouts (Nebula, Arvis) and ASC penetration create a durable competitive moat. Systems-driven conversions lock in recurring procedure-related revenue and market share gains, supporting sustainable top-line and margin expansion across orthopedics.
Improving Cash Generation And Capital DisciplineOperating and free cash flow have turned positive and improved, with management targeting >25% FCF conversion. This stronger cash generation and disciplined CapEx give the company funding flexibility to invest in Recon growth and innovation without excessive reliance on external financing.
Bears Say
Severe Operating And Net LossesThe company's large operating and net losses represent a structural profitability gap: despite revenue growth, the cost base has swung results to deeply negative margins. Sustained returns require either sustained margin expansion or material cost restructuring to restore positive earnings and ROE.
Tariff And Geopolitical ExposureOngoing tariff costs and recurring Middle East disruptions create persistent margin and revenue volatility. These external headwinds can erode incremental margins and force pricing or supply-chain adjustments, making earnings and cash generation more sensitive to macro and geopolitical developments.
Regulatory-driven Change To Adjusted EBITDAAn SEC-driven change to non-GAAP presentation reduces comparability of adjusted results and limits management's flexibility to present pro forma performance. This regulatory scrutiny increases reporting transparency risk and could make it harder to communicate normalized operating progress to investors.
ENOV FAQ
What was Enovis Corporation’s price range in the past 12 months?
Enovis Corporation lowest stock price was $19.14 and its highest was $36.82 in the past 12 months.
What is Enovis Corporation’s market cap?
Enovis Corporation’s market cap is $1.19B.
When is Enovis Corporation’s upcoming earnings report date?
Enovis Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 29 days.
How were Enovis Corporation’s earnings last quarter?
Enovis Corporation released its earnings results on May 07, 2026. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.812 by $0.078.
Is Enovis Corporation overvalued?
According to Wall Street analysts Enovis Corporation’s price is currently Undervalued.
Does Enovis Corporation pay dividends?
Enovis Corporation does not currently pay dividends.
What is Enovis Corporation’s EPS estimate?
Enovis Corporation’s EPS estimate is 0.85.
How many shares outstanding does Enovis Corporation have?
Enovis Corporation has 57,562,603 shares outstanding.
What happened to Enovis Corporation’s price movement after its last earnings report?
Enovis Corporation reported an EPS of $0.89 in its last earnings report, beating expectations of $0.812. Following the earnings report the stock price went up 9.658%.
Which hedge fund is a major shareholder of Enovis Corporation?
Currently, no hedge funds are holding shares in ENOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.33 (60.84% Upside)
$42.33 (60.84% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 563.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $92.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.71%
12-Months-Change
Fundamentals
Return on Equity
-60.13%
Trailing 12-Months
Asset Growth
-21.39%
Trailing 12-Months
Company Description
Enovis Corporation
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
ENOV Company Deck
ENOV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed solid operational execution and clear commercial momentum—particularly in Recon and extremities—with meaningful innovation catalysts (Arvis, Nebula), margin expansion at the gross level, EPS growth, and improved free cash flow. However, offsetting risks include tariff costs (~$4M), international volatility including Middle East exposure (~$1–2M/month), a Q1 selling-days headwind (~240 bps), a conservative stance on guidance, and an SEC-driven change to adjusted EBITDA presentation that reduces non-GAAP comparability. On balance, positive fundamental performance and a constructive outlook outweigh the near-term headwinds and reporting adjustments.View all ENOV earnings summariesENOV Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$42.33
▲(60.84% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
2.08% Insiders
34.85% Mutual Funds
31.93% Other Institutional Investors
0.29% Public Companies and
Individual Investors









